Literature DB >> 11576223

Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen.

M A Shokrgozar1, F Shokri.   

Abstract

Determination of the frequency of specific B lymphocytes has important implications for investigation of the immune response to different antigens and pathogens. Unresponsiveness to some viruses and antigens, such as hepatitis B virus (HBV) and its surface antigen (HBsAg), has been attributed to lack or insufficient production of the specific B-cell repertoire. In this study, peripheral blood B lymphocytes of 45 adult normal individuals vaccinated with recombinant hepatitis B vaccine were transformed with Epstein-Barr virus (EBV) and cultured at different dilutions on human fetal fibroblasts as a feeder layer. The vaccinees were classified into good, poor and non-responder groups. Following 2 to 3 weeks of incubation, culture supernatants were collected from wells containing transformed and proliferating B lymphocytes. The supernatants were subsequently screened for the presence of total immunoglobulin and antibody to HBsAg (anti-HBs) by enzyme-linked immunosorbent assay (ELISA). Accordingly, positive and negative wells were enumerated in each plate and the frequency of B lymphocytes producing anti-HBs antibody was estimated based on the Poisson statistical analysis. The total number of CD19+ B lymphocytes were counted in the peripheral blood of all subjects by flow cytometry. Our results demonstrated a similar precursor frequency of specific B lymphocytes in all subject groups before vaccine administration (< 2 x 10(-5)). Following vaccination, however, a significant increase in the number of specific B lymphocytes was observed in good-responder (1.5 x 10(-4)) and to a lesser extent poor-responder (3.5 x 10(-5)) individuals, but not in non-responders. These findings suggest a defect in either the primary B-cell repertoire or helper T-cell function in non-responder individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576223      PMCID: PMC1783286          DOI: 10.1046/j.1365-2567.2001.01273.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes.

Authors:  V Barnaba; A Franco; A Alberti; R Benvenuto; F Balsano
Journal:  Nature       Date:  1990-05-17       Impact factor: 49.962

2.  Defect in Th1-like cells of nonresponders to hepatitis B vaccine.

Authors:  M G Chedid; H Deulofeut; D E Yunis; M L Lara-Marquez; M Salazar; R Deulofeut; Z Awdeh; C A Alper; E J Yunis
Journal:  Hum Immunol       Date:  1997-11       Impact factor: 2.850

3.  The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg.

Authors:  T Höhler; C U Meyer; A Notghi; B Stradmann-Bellinghausen; P M Schneider; R Starke; F Zepp; R Sänger; R Clemens; K H Meyer zum Büschenfelde; C Rittner
Journal:  Hum Immunol       Date:  1998-04       Impact factor: 2.850

4.  High rate of seroconversion following administration of a single supplementary dose of recombinant hepatitis B vaccine in Iranian healthy nonresponder neonates.

Authors:  F Shokri; A Amani
Journal:  Med Microbiol Immunol       Date:  1997-03       Impact factor: 3.402

5.  Normal HBsAg presentation and T-cell defect in the immune response of nonresponders.

Authors:  M Salazar; H Deulofeut; C Granja; R Deulofeut; D E Yunis; D Marcus-Bagley; Z Awdeh; C A Alper; E J Yunis
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes.

Authors:  I Desombere; P Hauser; R Rossau; J Paradijs; G Leroux-Roels
Journal:  J Immunol       Date:  1995-01-15       Impact factor: 5.422

7.  Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals.

Authors:  H Deulofeut; A Iglesias; N Mikael; D H Bing; Z Awdeh; J Yunis; D Marcus-Bagley; M S Kruskall; C A Alper; E J Yunis
Journal:  Mol Immunol       Date:  1993-07       Impact factor: 4.407

8.  Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus.

Authors:  Y Ueki; I S Goldfarb; N Harindranath; M Gore; H Koprowski; A L Notkins; P Casali
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

9.  Expression of VHIII-associated cross-reactive idiotype on human B lymphocytes. Association with staphylococcal protein A binding and Staphylococcus aureus Cowan I stimulation.

Authors:  F Shokri; R A Mageed; B R Maziak; R Jefferis
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

10.  Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production.

Authors:  J Vingerhoets; G Vanham; L Kestens; G Penne; G Leroux-Roels; P Gigase
Journal:  Immunol Lett       Date:  1994-02       Impact factor: 3.685

View more
  13 in total

1.  The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates.

Authors:  A Jafarzadeh; F Shokri
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

2.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines.

Authors:  Vijayakumar Velu; Shanmugam Saravanan; Subhadra Nandakumar; Esaki-Muthu Shankar; Appasamy Vengatesan; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

3.  Novel antibody against TMX2 and its effects on breast cancer cells.

Authors:  Eleana Hatzidaki; Dimitrios A Ntanovasilis; Ioannis Papasotiriou
Journal:  Int J Biochem Mol Biol       Date:  2020-02-15

4.  HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt.

Authors:  Eman Ae Abushady; Magda Ma Gameel; John D Klena; Salwa F Ahmed; Kouka Se Abdel-Wahab; Sanya M Fahmy
Journal:  World J Hepatol       Date:  2011-06-27

5.  Differential reactivity of mouse monoclonal anti-HBs antibodies with recombinant mutant HBs antigens.

Authors:  Azam Roohi; Yaghoub Yazdani; Jalal Khoshnoodi; Seyed Mohammad Jazayeri; William F Carman; Mahmood Chamankhah; Manley Rashedan; Fazel Shokri
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

Review 6.  Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.

Authors:  Hsin-Yun Sun; Wang-Huei Sheng; Mao-Song Tsai; Kuan-Yeh Lee; Sui-Yuan Chang; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 7.  Prevention of hepatitis B virus infection: from the past to the future.

Authors:  R Orlando; M Foggia; A E Maraolo; S Mascolo; G Palmiero; O Tambaro; G Tosone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-13       Impact factor: 3.267

8.  Antibody detection and kinetics of antibody production during early stages of immunization with hepatitis B virus vaccine.

Authors:  Odd Odinsen; Shirley Owusu-Ofori; Albert Dompreh; Francis Sarkodie; Ohene Opare-Sem; David Parker; Jean-Pierre Allain
Journal:  Clin Vaccine Immunol       Date:  2007-10-10

9.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

Review 10.  Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease.

Authors:  Alicia C Marín; Javier P Gisbert; María Chaparro
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.